Ann: Trading Halt, page-13

Any financing deal will be good - there’s massive opportunity here and we are reaching the pointy end now.

James has secured the Chinese deal surprising everyone for around 8-9% of global population and a deal worth hundreds of millions - then again the Cantrixil deal when some here predicted it was worthless - 40 million dollar milestone payment structure and around 12% royalty was achieved…

there’s no doubt whatever the deal it’s beneficial at this juncture - we are expecting GBM Agile to finalise this year - next step FDA application

and all eyes will then turn to DiPG and all the other studies - as this is a pivotal year for Pax

The there’s EVT - interesting to see how this new compound performs